

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) MAY 20, 1996

ENZON, INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)	0-12957 (Commission File Number)	22-237286 (IRS Employer Identification)
---	--	---

20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY (Address of principal executive offices)	08854 (Zip Code)
---	---------------------

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

Enzon, Inc. ("Enzon" or the "Company") completed its Phase Ia clinical trial in healthy volunteers at the end of 1995, and received approval from the FDA to enter a multi-dose trial in cancer patients. Enrollment of patients for this trial has been unexpectedly slow, and as a result, the Company has just opened a second site and plans to add additional sites. The clinical supplies for the trial have been delivered to the open sites. To expedite completion of this trial, a clinical research organization will be utilized to accelerate patient recruitment, monitor the study, and compile results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 29, 1996

ENZON, INC.
(Registrant)

By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer